The challenge of progressive hepatitis C following liver transplantation

Liver Transplantation

Volumn 12, Issue 1, 2006, Pages 19-21

  Davis, Gary L ^a  

^a BAYLOR UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIFIBROTIC AGENT; AZATHIOPRINE; CALCINEURIN INHIBITOR; CYCLOSPORIN; HYPERIMMUNE GLOBULIN; INTERFERON; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PROTEINASE INHIBITOR; RIBAVIRIN; STEROID; TSUKUBAENOLIDE; VIRUS ANTIBODY;

DRUG DOSE REDUCTION; DRUG RESPONSE; EDITORIAL; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY DYSFUNCTION; LIVER BIOPSY; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; PRIORITY JOURNAL; RECURRENT INFECTION;

CYCLOSPORINE; DISEASE PROGRESSION; GRAFT REJECTION; GRAFT SURVIVAL; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LIVER FAILURE; LIVER TRANSPLANTATION; POSTOPERATIVE COMPLICATIONS; RECURRENCE; SENSITIVITY AND SPECIFICITY;

EID: 33645106100     PISSN: 15276465     EISSN: 15276473     Source Type: Journal    
DOI: 10.1002/lt.20576     Document Type: Editorial

References (31)

1. Organ Procurement and Transplantation Network (OPTN) database. Available at: http://www.optn.org. Last accessed: September 14, 2005.
2. Armstrong GL, Alter MJ, McQuillan GM, Margolis HS. The past incidence of hepatitis C virus infection: implications for the future burden of chronic liver disease in the United States. Hepatology 2000;31:777-782.
3. Davis GL, Albright JE, Cook SF, Rosenberg DM. Projecting the future healthcare burden from hepatitis C in the United States. Liver Transpl 2003;9:331-338.
4. Wright TL, Donegan E, Hsu HH, Farrell L, Lake JR, Kim M, et al. Recurrent and acquired hepatitis C viral infection in liver transplant recipients. Gastroenterology 1992;103:317-322.
5. Everson GT. Impact of immunosuppressive therapy on recurrence of hepatitis C. Liver Transpl 2002;8(10 Suppl 1):S19-S27.
6. Berenguer M, Ferrell L, Watson J, Prieto M, Kim M, Rayon M, et al. HCV-related fibrosis progression following liver transplantation: Increase in recent years. J Hepatol 2000; 32:673-684.
7. Fattovich G, Giustina G, Degos F, Tremolada F, Diodati G, Almasio P, et al. Morbidity and mortality in compensated cirrhosis type C: a retrospective follow-up study of 384 patients. Gastroenterology 1997;112:463-472.
8. Willems B, Ede M, Marotta P, Wall W, Greig P, Lilly L, et al. Anti-HCV human immunoglobulins for the prevention of graft infection in HCV-related liver transplantation, a pilot study. (Abstract). J Hepatol 2002;36(Suppl 1):32.
9. Davis GL, Nelson DR, Terrault N, Pruett TL, Shiano TD, Fletcher CV, et al. A randomized, open-label study to evaluate the safety and pharmacokinetics of human hepatitis C immune globulin (Civacir) in liver transplant recipients. Liver Transpl 2005;11:941-949.
10. Firpi RJ, Abdelmalek MF, Soldevila-Pico C, Reed A, Hemming A, Howard R, et al. Combination of interferon alfa-2b and ribavirin in liver transplant recipients with histological recurrent hepatitis C. Liver Transpl 2002;8:1000-1006.
11. Castells L, Vargas V, Allende H, Bilboa I, Luis Lazaro J, Margarit C, et al. Combined treatment with pegylated interferon (alpha-2b) and ribavirin in the acute phase of hepatitis C virus recurrence after liver transplantation. J Hepatol 2005;43:53-59.
12. Davis GL. Chronic hepatitis C and liver transplantation. Rev Gastroenterol Disord 2004;4:7-17.
13. Neumann UP, Berg T, Bahra M, Puhl G, Guckelberger O, Langehr JM, Neuhaus P. Long-term outcome of liver transplants for chronic hepatitis C: a 10-year follow-up. Transplantation 2004;77:226-231.
14. Bahra M, Neumann UP, Jacob D, Langrehr JM, Berg T, et al. Repeated steroid pulse therapies in HCV-positive liver recipients: significant risk factor for HCV-related graft loss. Transplant Proc 2005;37:1700-1702.
15. Washburn K, Speeg KV, Esterl R, Gigarroa F, Pollack M, Tourtellot C, et al. Steroid elimination 24 hours after liver transplantation using daclizumab, tacrolimus, and mycophenolate mofetil. Transplantation 2001;72:1675-1679.
16. Fasola CG, Heffron TG, Sher L, Douglas DD, Brown R, Ham J, et al. Multicenter randomized hepatitis C (HCV) three trial post liver transplantation (OLT): a one-year follow up report (abstract). Am J Transplant 2005;5(Suppl 11):276.
17. Fisher RA, Stone JJ, Wolfe LG, Rodgers CM, Anderson ML, Sterling RK, et al. Four-year follow-up of a prospective randomized trial of mycophenolate mofetil with cyclosporine microemulsion or tacrolimus following liver transplantation. Clin Transplant 2004;18:463-472.
18. Bahr MJ, Beckermann JG, Rifai K, Gehrmann L, Rosenau J, Klempnauer J, et al. Retrospective analysis of the impact of immunosuppression on the course of recurrent hepatitis C after liver transplantation. Transplant Proc 2005;37:1703-1704.
19. Wiesner RH. A long-term comparison of tacrolimus (FK506) versus cyclosporine in liver transplantation: a report of the United States FK506 Study Group. Transplantation 1998;66:493-499.
20. Ghobrial RM, Farmer DG, Baquerizo A, Colquhoun S, Rosen HR, Yersiz H, et al. Orthotopic liver transplantation for hepatitis C: outcome, effect of immunosuppression, and causes of retransplantation during an 8-year single-center experience. Ann Surg 1999;229:824-831.
21. Martin P, Busuttil RW, Goldstein RM, Crippin JS, Klintmalm GB, Fitzsimmons WE, Uleman C. Impact of tacrolimus versus cyclosporine in hepatitis C virus-infected liver transplant recipients on recurrent hepatitis: a prospective, randomized trial. Liver Transpl 2004;10:1258-1262.
22. The U.S. Multicenter FK506 Liver Study Group. A comparison of tacrolimus (FK506) and cyclosporine for immunosuppression in liver transplantation. N Engl J Med 1994;331:1154-1155.
23. Nakagawa M, Sakamoto N, Enomoto N, Tanabe Y, Kanazawa N, Koyama T, et al. Specific inhibition of hepatitis C virus replication by cyclosporin A. Biochem Biophys Res Commun 2004;313:42-47.
24. Firpi RJ, Zhu H, Morelli G, et al. Cyclosporine suppresses hepatitis C virus in vitro and increases the chance of a sustained virological response after liver transplantation. Liver Transpl 2006;12:51-57.
25. Stravitz RT, Shiffman ML, Sanyal AJ, Luketic VA, Sterling RK, Heuman DM, et al. Effects of interferon treatment on liver histology and allograft rejection in patients with recurrent hepatitis C following liver transplantation. Liver Transpl 2004;10:850-858.
26. Dumortier J, Scoazec JY, Chevallier P, Boillot O. Treatment of recurrent hepatitis C after liver transplantation: a pilot study of peginterferon alfa-2b and ribavirin combination. J Hepatol 2004;40:669-674.
27. Samuel D, Bizollon T, Feray C, Roche B, Ahmed SN, Lemonnier C, et al. Interferon-alpha 2b plus ribavirin in patients with chronic hepatitis C after liver transplantation: a randomized study. Gastroenterology 2003;124:642-650.
28. Lavezzo B, Franchello A, Smedile A, David E, Barbui A, Torrani M, et al. Treatment of recurrent hepatitis C in liver transplants: efficacy of a six versus a twelve month course of interferon alfa 2b with ribavirin. J Hepatol 2002;37: 247-252.
29. Narayanan Menon KV, Poterucha JJ, El-Amin OM, Burgart LJ, Kremers WK, Rosen CB, et al. Treatment of post-transplantation recurrence of hepatitis C with interferon and ribavirin: lessons on tolerability and efficacy. Liver Transpl 2002;8:623-629.
30. Abdelmalek MF, Firpi RJ, Soldevila-Pico C, Reed AI, Hemming AW, Liu C, et al. Sustained viral response to interferon and ribavirin in liver transplant recipients with recurrent hepatitis C. Liver Transpl 2004;10:199-207.
31. Chalasani N, Manzarbeitia C, Ferenci P, Vogel W, Fontana RJ, Voigt M, et al. Peginterferon alfa-2a for hepatitis C after liver transplantation: two randomized, controlled trials. Hepatology. 2005;41:289-298.